References
1. National institute of infectious diseases. Infectious Agents
Surveillance Report. 2021; 42 : 155-67.
2. O’Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections:
epidemiology, clinical manifestations, and optimal management. Infect
Drug Resist. 2015; 8 : 217-30.
3. Prematunge C, MacDougall C, Johnstone J, et al. VRE and VSE
bacteremia outcomes in the era of effective VRE therapy: A systematic
review and meta-analysis. Infect Control Hosp Epidemiol. 2016;37 : 26-35.
4. Miller WR, Murray BE, Rice LB, Arias CA. Vancomycin-resistant
enterococci: Therapeutic challenges in the 21st century. Infect Dis Clin
North Am. 2016; 30 : 415-39.
5. Tacconelli E and Cataldo MA. Vancomycin-resistant enterococci (VRE):
transmission and control. Int J Antimicrob Agents. 2008;31 :99-106.
6. Hayakawa K, Mezaki K, Sugiki Y, et al. High rate of
multidrug-resistant organism colonization among patients hospitalized
overseas highlights the need for preemptive infection control. Am J
Infect Control. 2016; 44 : e257-9.
7. Medina-Polo J, Sopena-Sutil R, Benitez-Sala R, et al. Prospective
study analyzing risk factors and characteristics of
healthcare-associated infections in a urology ward. Investig Clin Urol.
2017; 58 : 61-9.